# Oncology Medical Scenarios

## Scenario 1: Newly Diagnosed Breast Cancer

### Patient Profile
- **Name:** Jennifer Martinez
- **Age:** 48 years
- **Gender:** Female
- **Weight:** 145 lbs (66 kg)
- **Height:** 5'6" (168 cm)
- **BMI:** 23.4
- **Occupation:** Teacher

### Medical History
- **Primary:** Stage IIA Invasive Ductal Carcinoma
- **Family History:** Sister diagnosed with breast cancer at age 42, Mother with ovarian cancer at age 65
- **Gyn History:** Menarche age 12, regular menstrual cycles, 2 children (ages 20 and 18)
- **Social History:** Non-smoker, occasional alcohol use
- **Medications:** None

### Chief Complaint
"I found a lump in my right breast during self-examination. My doctor ordered some tests and called me with the results."

### Physical Examination
- **General:** Well-appearing, appropriate for age
- **Breast Exam:** 2.5 cm hard, fixed mass in upper outer quadrant right breast
- **Regional Nodes:** Palpable right axillary lymph nodes (2 nodes, ~1 cm each)
- **Systemic:** No organomegaly, no other masses

### Diagnostic Results
- **Biopsy:** Invasive ductal carcinoma, ER+/PR+, HER2/neu negative
- **Mammogram:** 2.6 cm mass, BI-RADS 5
- **Breast MRI:** Enhanced mass, no additional lesions
- **Staging Workup:**
  - Chest CT: No pulmonary metastases
  - Abdominal CT: No hepatic metastases
  - Bone scan: No bone metastases
  - Tumor markers: CA 15-3 mildly elevated
- **Final Staging:** T2N1M0, Stage IIA

### Clinical Decision Points

#### Multidisciplinary Treatment Planning
1. **Surgical Options:**
   - Breast-conserving therapy (lumpectomy + radiation)
   - Mastectomy with reconstruction options

2. **Systemic Therapy Considerations:**
   - **Chemotherapy:** Due to node-positive disease
   - **Hormone therapy:** ER+/PR+ receptor positive
   - **Targeted therapy:** HER2 negative (no trastuzumab needed)

3. **Radiation Planning:**
   - Whole breast radiation after lumpectomy
   - Axillary radiation consideration

#### Risk Assessment Tools
- **Oncotype DX Score:** Recommended for treatment decision-making
- **Age:** 48 years (close to menopause consideration)
- **Lymph node status:** 1-3 positive nodes

### Treatment Plan

#### Neoadjuvant Treatment (Pre-operative)
1. **Chemotherapy:**
   - AC-T regimen (Adriamycin/Cyclophosphamide followed by Paclitaxel)
   - Duration: 4 cycles AC + 4 cycles T (4 months total)

2. **Response Assessment:**
   - Clinical response evaluation
   - Imaging after neoadjuvant therapy

#### Surgical Treatment
- **Lumpectomy** with sentinel lymph node biopsy
- **Post-surgical pathology** determines need for additional surgery

#### Adjuvant Treatment
1. **Radiation Therapy:**
   - 50 Gy to whole breast + boost to tumor bed
   - Daily treatment for 6-7 weeks

2. **Hormone Therapy:**
   - Tamoxifen 20mg daily (5 years) if premenopausal
   - Aromatase inhibitor consideration if postmenopausal

3. **Surveillance:**
   - Annual mammography
   - Clinical visits every 3-6 months for 2 years
   - CA 15-3 monitoring

### Learning Objectives
- Integrate staging information for treatment planning
- Understand multidisciplinary cancer care
- Apply evidence-based adjuvant therapy decisions
- Recognize hereditary cancer syndromes
- Coordinate comprehensive cancer care

---

## Scenario 2: Metastatic Colon Cancer

### Patient Profile
- **Name:** David Thompson
- **Age:** 62 years
- **Gender:** Male
- **Weight:** 165 lbs (75 kg)
- **Height:** 5'9" (175 cm)
- **BMI:** 24.5
- **Occupation:** Retired accountant

### Medical History
- **Primary:** Metastatic adenocarcinoma of sigmoid colon
- **Medical History:** Hypertension, type 2 diabetes
- **Social History:** Former smoker (quit 15 years ago)
- **Medications:** Metformin 1000mg BID, Lisinopril 10mg daily

### Chief Complaint
"I've been having changes in my bowel habits and some blood in my stool. My doctor did a colonoscopy and found something concerning."

### Presentation Timeline
- **3 months ago:** Gradual onset of constipation
- **2 months ago:** Intermittent bright red blood per rectum
- **1 month ago:** Unintentional weight loss (15 lbs)
- **2 weeks ago:** Colonoscopy performed

### Diagnostic Results
- **Colonoscopy:** Sigmoid colon mass, 4 cm, partially obstructing
- **Biopsy:** Moderately differentiated adenocarcinoma
- **Staging CT:**
  - Primary: Sigmoid colon mass with regional lymphadenopathy
  - Liver: Multiple bilateral hepatic metastases (largest 3.2 cm)
  - Lungs: Small bilateral pulmonary nodules
- **CEA:** Elevated (45 ng/mL)
- **Molecular Testing:** KRAS wild-type, MSI-stable

### Clinical Decision Points

#### Metastatic Disease Management
1. **Treatment Goals:**
   - Palliative intent (not curative)
   - Prolong survival
   - Maintain quality of life
   - Control symptoms

2. **First-Line Treatment Options:**
   - FOLFOX or FOLFIRI chemotherapy
   - Biological agents (bevacizumab, cetuximab)
   - Location of primary tumor consideration

#### Symptom Management
- **Obstructive symptoms:** Endoscopic stenting or surgery
- **Anemia:** Consider transfusion if symptomatic
- **Pain management:** Opioid and adjuvant medications

### Treatment Plan

#### First-Line Systemic Therapy
1. **Chemotherapy:** FOLFOX6 regimen
   - Oxaliplatin 85 mg/m² IV
   - Leucovorin 400 mg/m² IV
   - Fluorouracil 400 mg/m² IV bolus + 2400 mg/m² continuous infusion
   - Cycle every 2 weeks

2. **Biological Therapy:** Bevacizumab 5 mg/kg IV
   - Anti-VEGF therapy
   - Monitor for hypertension, bleeding, proteinuria

#### Supportive Care
1. **Symptom Management:**
   - Pain control regimen
   - Antiemetics during chemotherapy
   - Nutritional support

2. **Monitoring:**
   - CBC, CMP every 2 weeks
   - CEA every 4 weeks
   - CT scans every 8 weeks (RECIST criteria)

#### Second-Line Considerations
- **Progression:** Switch to FOLFIRI + bevacizumab
- **KRAS wild-type:** Consider EGFR inhibitor
- **Clinical trials:** Always consider enrollment

### Prognosis and Goals
- **Median survival:** 24-30 months with modern therapy
- **Quality of life focus:** Maintain independence and function
- **Goals:** Treatment breaks for quality of life

### Learning Objectives
- Manage metastatic colorectal cancer
- Apply systemic therapy principles
- Understand palliative care integration
- Coordinate multidisciplinary oncology care
- Support patients and families through treatment

---

## Scenario 3: Acute Lymphoblastic Leukemia

### Patient Profile
- **Name:** Marcus Johnson
- **Age:** 24 years
- **Gender:** Male
- **Weight:** 170 lbs (77 kg)
- **Height:** 5'11" (180 cm)
- **BMI:** 23.7
- **Occupation:** Graduate student

### Medical History
- **Primary:** B-cell acute lymphoblastic leukemia (ALL)
- **Medical History:** None significant
- **Social History:** Non-smoker, healthy lifestyle
- **Family History:** No significant hematologic malignancies

### Chief Complaint
"I've been feeling extremely tired for the past month. I have some bone pain and noticed I'm bruising easily."

### Clinical Presentation
- **3 weeks ago:** Gradual onset fatigue
- **2 weeks ago:** Easy bruising, petechiae
- **1 week ago:** Bone pain (ribs, spine)
- **2 days ago:** Fever 101.8°F (38.8°C)

### Physical Examination
- **Vital Signs:** T 101.8°F, HR 110, BP 140/80, RR 20
- **General:** Appears ill, pale, lethargic
- **Skin:** Petechiae on arms and legs, ecchymoses
- **Lymph Nodes:** Bilateral cervical lymphadenopathy
- **Hepatosplenomegaly:** Liver 2 cm below costal margin, spleen 4 cm below costal margin

### Laboratory Results
- **CBC:**
  - WBC: 45,000/μL (elevated)
  - Hemoglobin: 7.2 g/dL
  - Platelets: 25,000/μL (severely low)
  - Blasts: 65% in peripheral smear
- **Chemistry:**
  - LDH: 850 U/L (elevated)
  - Uric acid: 8.5 mg/dL (elevated)
  - Creatinine: 1.2 mg/dL
- **Coagulation:** PT/PTT slightly elevated
- **Flow Cytometry:** CD10+, CD19+, CD20+ (B-ALL phenotype)
- **Cytogenetics:** Philadelphia chromosome negative

### Clinical Decision Points

#### Immediate Management Needs
1. **Tumor Lysis Syndrome Prevention:**
   - Aggressive hydration
   - Allopurinol or rasburicase
   - Monitor electrolytes closely

2. **Infection Prevention:**
   - Broad-spectrum antibiotics
   - Antifungal prophylaxis
   - Neutropenic precautions

3. **Transfusion Support:**
   - Platelet transfusion (platelets <10,000/μL)
   - Packed RBC transfusion (Hgb <8 g/dL)

#### Treatment Strategy
- **Induction chemotherapy** (4-6 weeks)
- **Consolidation therapy** (6-8 months)
- **Maintenance therapy** (2-3 years)
- **CNS prophylaxis** (intrathecal therapy)

### Treatment Plan

#### Induction Phase
1. **Vincristine, Doxorubicin, Prednisone, L-asparaginase**
2. **CNS prophylaxis:** Intrathecal methotrexate
3. **Supportive care:** Transfusions, growth factors

#### Consolidation Phase
1. **High-dose methotrexate**
2. **Cycle-dependent chemotherapy**
3. **MRD monitoring:** Flow cytometry for minimal residual disease

#### Maintenance Phase
- **6-Mercaptopurine and methotrexate**
- **Duration:** 2-3 years
- **Monthly vincristine and prednisone pulses**

### Prognosis and Goals
- **Complete remission rate:** 85-90% in young adults
- **Long-term cure rate:** 40-50%
- **Goal:** Achieve and maintain complete remission

### Learning Objectives
- Recognize acute leukemia presentation
- Manage complications of acute leukemia
- Understand ALL treatment protocols
- Provide supportive care during chemotherapy
- Monitor for treatment toxicities

---

## Scenario 4: Non-Small Cell Lung Cancer

### Patient Profile
- **Name:** Linda Chen
- **Age:** 65 years
- **Gender:** Female
- **Weight:** 130 lbs (59 kg)
- **Height:** 5'4" (163 cm)
- **BMI:** 22.4
- **Occupation:** Retired nurse

### Medical History
- **Primary:** Stage IIIA adenocarcinoma of lung
- **Smoking History:** Former smoker, 40 pack-year history (quit 5 years ago)
- **Medical History:** COPD (moderate), hypertension
- **Medications:** Albuterol PRN, Lisinopril 10mg daily

### Chief Complaint
"I have a persistent cough that hasn't gone away for 3 months, and I've been coughing up some blood."

### Clinical Timeline
- **3 months ago:** Persistent dry cough
- **6 weeks ago:** Hemoptysis (small amount of blood)
- **1 month ago:** Chest X-ray showing right upper lobe mass
- **2 weeks ago:** CT chest and biopsy completed

### Diagnostic Results
- **CT Chest:** 3.5 cm right upper lobe mass, right hilar lymphadenopathy
- **PET/CT:** Hypermetabolic primary mass and mediastinal nodes
- **Biopsy:** Adenocarcinoma, moderately differentiated
- **Molecular Testing:**
  - EGFR: Wild-type
  - ALK: Negative
  - ROS1: Negative
  - PD-L1: 80% (high expression)
- **Pulmonary Function:** FEV1 65% predicted

### Clinical Decision Points

#### Staging Confirmation
- **Stage IIIA (T2N2M0):**
  - T2: Primary tumor >3 cm, involves visceral pleura
  - N2: Ipsilateral mediastinal lymph nodes
  - M0: No distant metastases

#### Treatment Options
1. **Concurrent Chemoradiation:**
   - Standard of care for unresectable stage III NSCLC
   - 60-66 Gy radiation + platinum doublet chemotherapy

2. **Immunotherapy:**
   - Durvalumab consolidation post-chemoradiation
   - PD-L1 high expression supports use

3. **Surgery Consideration:**
   - Limited role in N2 disease
   - Requires multidisciplinary evaluation

### Treatment Plan

#### Concurrent Chemoradiation
1. **Radiation Therapy:**
   - 60 Gy in 30 fractions
   - 6 weeks, Monday-Friday
   - IMRT technique

2. **Chemotherapy:**
   - Carboplatin (AUC 2) + Paclitaxel (50 mg/m²) weekly
   - Concurrent with radiation

#### Consolidation Immunotherapy
- **Durvalumab 10 mg/kg IV every 2 weeks**
- **Duration:** Up to 12 months
- **Monitor for immune-related adverse events**

#### Supportive Care
1. **Smoking cessation counseling**
2. **Pulmonary rehabilitation**
3. **Symptom management:**
   - Antitussives for cough
   - Bronchodilators for COPD
   - Pain management

### Follow-up Schedule
- **Months 1-6:** Monthly visits during concurrent therapy
- **Months 6-18:** Every 2 months
- **Imaging:** CT chest every 3 months for 2 years

### Learning Objectives
- Integrate staging and molecular testing results
- Apply concurrent chemoradiation protocols
- Understand immunotherapy in lung cancer
- Manage treatment-related toxicities
- Coordinate multidisciplinary cancer care

---

## Additional Oncology Scenarios

### Chronic Myeloid Leukemia (CML)
- **Patient:** 45-year-old male with fatigue and splenomegaly
- **Key points:** Philadelphia chromosome, TKI therapy, molecular monitoring
- **Learning objectives:** Targeted therapy principles

### Multiple Myeloma
- **Patient:** 68-year-old female with bone pain and anemia
- **Key points:** Plasma cell disorder, CRAB criteria, stem cell transplant
- **Learning objectives:** Hematologic malignancy management

### Melanoma with Brain Metastases
- **Patient:** 52-year-old male with melanoma and new neurological symptoms
- **Key points:** Immunotherapy, brain metastases, targeted therapy
- **Learning objectives:** Metastatic disease management

---

## References and Guidelines

### Primary Guidelines
1. **NCCN Clinical Practice Guidelines in Oncology (2024)**
   - Breast Cancer
   - Colon Cancer
   - Acute Lymphoblastic Leukemia
   - Non-Small Cell Lung Cancer

2. **American Society of Clinical Oncology (ASCO) Guidelines**
3. **European Society for Medical Oncology (ESMO) Guidelines**

### Key Evidence Sources
- CALGB trials (breast cancer)
- CALGB/Intergroup trials (colon cancer)
- CALGB studies (ALL)
- PACIFIC trial (durvalumab in NSCLC)

### Quality Metrics
- Time to cancer treatment initiation
- Appropriate staging workup completion
- Clinical trial enrollment rates
- Symptom assessment documentation

---

*Note: All scenarios are fictional and created for educational purposes. Patient information has been de-identified and modified for demonstration.*